BTSG logo

BrightSpring Health Services, Inc. Stock Price

NasdaqGS:BTSG Community·US$14.5b Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 17 Fair Values set on narratives written by author

BTSG Share Price Performance

US$68.98
45.44 (193.03%)
US$70.00
Fair Value
US$68.98
45.44 (193.03%)
1.5% undervalued intrinsic discount
US$70.00
Fair Value
Price US$68.98
AnalystHighTarget US$70.00
prajeesh US$70.59
AnalystConsensusTarget US$59.60

BTSG Community Narratives

·
Fair Value US$70 1.5% undervalued intrinsic discount

Aging Population Will Transform Home And Community Integrated Care

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Fair Value
·
Fair Value US$70.59 2.3% undervalued intrinsic discount

BrightSpring Health Services will shine with future PE rising 69.72x

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value US$59.6 15.7% overvalued intrinsic discount

Analysts Raise Targets as BrightSpring Health Services Sees Improved Margins and Growth Outlook

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
US$70.59
2.3% undervalued intrinsic discount
Fair Value
Revenue
12.67% p.a.
Profit Margin
1.25%
Future PE
69.72x
Price in 2031
US$99.5
US$59.6
15.7% overvalued intrinsic discount
Revenue
14.66% p.a.
Profit Margin
2.95%
Future PE
26.75x
Price in 2029
US$73.19

Trending Discussion

Updated Narratives

BTSG logo

BrightSpring Health Services will shine with future PE rising 69.72x

Fair Value: US$70.59 2.3% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
BTSG logo

BTSG: Rich Multiple Will Hinge On Fragile Generic Conversion Outlook

Fair Value: US$50.78 35.8% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
BTSG logo

BTSG: Acquisition Integration And Generic Conversion Execution Will Drive Future Upside Potential

Fair Value: US$70 1.5% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Adequate balance sheet with moderate growth potential.

1 Risk
3 Rewards

BrightSpring Health Services, Inc. Key Details

US$13.6b

Revenue

US$12.0b

Cost of Revenue

US$1.7b

Gross Profit

US$1.5b

Other Expenses

US$171.0m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
0.82
12.18%
1.25%
125.5%
View Full Analysis

About BTSG

Founded
1974
Employees
23500
CEO
Jon Rousseau
WebsiteView website
www.brightspringhealth.com

BrightSpring Health Services, Inc. operates as a home and community-based healthcare services platform in the United States. The company operates through two segments, Pharmacy Solutions and Provider Services. Its platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It also offers infused, injectable, and oral medication services; and patient-centric, highly skilled, and compassionate clinical home health care, as well as rehabilitation services, including physical, speech and occupational therapy and applied behavioral analysis. The company was formerly known as Phoenix Parent Holdings Inc. and changed its name to BrightSpring Health Services, Inc. in May 2021. BrightSpring Health Services, Inc. was founded in 1974 and is headquartered in Louisville, Kentucky.

Recent BTSG News & Updates

Narrative Update Jun 22

BTSG: Rich Multiple Will Hinge On Fragile Generic Conversion Outlook

Analysts have nudged their BrightSpring Health Services fair value estimate slightly higher to about $50.78 per share, pointing to recent price target increases into the $66 to $81 range. They cite the company's specialty pharmacy exposure, home- and community-based care focus, acquisition track record, and expectations around future generic drug opportunities as key supports for the new view.

Recent updates

No updates